<DOC>
	<DOCNO>NCT00712634</DOCNO>
	<brief_summary>RATIONALE : Vaccines may help body build effective immune response cytomegalovirus . PURPOSE : This randomized phase I trial study side effect best dose cytomegalovirus vaccine healthy participant .</brief_summary>
	<brief_title>Cytomegalovirus Vaccine Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : - To establish whether 4 dose level CMVpp65-A*0201 peptide vaccine safe well tolerate cytomegalovirus ( CMV ) -seropositive participant . - To determine whether CMVpp65-A*0201 peptide vaccine , give single injection follow one booster injection safe well-tolerated dose , capable stimulate memory response CMV-seropositive participant . - To evaluate whether CMV-seronegative participant generate de novo immune response CMV immunization CMVpp65-A*0201 peptide vaccine give single injection follow three booster injection . - To determine duration immune enhancement CMV-specific cytotoxic T-lymphocyte function assess 12 month primary secondary immunization CMVpp65-A*0201 peptide vaccine . OUTLINE : This dose-escalation study CMVpp65-A*0201 peptide vaccine cytomegalovirus ( CMV ) -seropositive participant . Once safe dose establish , CMV-seronegative participant accrue immunized dose . Participants stratify accord gender . - CMV-seropositive participant : Participants randomize receive 1 4 escalate dos CMVpp65-A*0201 peptide vaccine contain either helper T-lymphocyte ( HTL ) PADRE peptide HTL tetanus toxoid peptide . Within vaccine dose group , two participant randomize receive placebo . Participants receive vaccine placebo subcutaneously ( SC ) day 0 28 absence unacceptable toxicity . - CMV-seronegative participant : Participants randomize receive 1 4 establish dos ( establish CMV-seropositive participant ) CMVpp65-A*0201 peptide vaccine contain either HTL PADRE peptide HTL tetanus toxoid peptide . Participants receive vaccine day 0 , 28 , 56 absence unacceptable toxicity . Participants partial low-level immune response receive one additional booster vaccine day 90 . Participants undergo blood sample collection baseline periodically study immunologic laboratory study . Participants also undergo skin biopsy baseline . Laboratory study include assessment human cytotoxic T-lymphocyte activity response ^51chromium-release assay , limiting-dilution analysis , T-cell proliferation assay ; CD4/CD8 phenotyping FACScan® flow cytometry . After completion study therapy , participant follow 12 month .</detailed_description>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant Cytomegalovirus seropositive seronegative HLAA*0201positive PATIENT CHARACTERISTICS : CBC within 1.5 time normal SMA18 within 1.5 time normal Hepatitis B virus antigen seronegative Hepatitis C virus seronegative No diagnosis associate immunodeficiency , include HIV infection No serious abnormality EKG ( participant ≥ 50 year age ) Not pregnant PRIOR CONCURRENT THERAPY : More 6 month since prior surgery No concurrent daily medication chronic current illness , except follow : Thyroid replacement therapy Estrogen replacement therapy Dietary vitamin protein supplement Antihistamine medication Anticholesterol medication Cardiac antihypertensive medication Any medication , determine principal investigator , know likely immunosuppressive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>cytomegalovirus infection</keyword>
</DOC>